A Pfizer emblem is displayed at a analysis facility within the La Jolla neighborhood of San Diego, California, U.S., Sept. 30, 2025.
Mike Blake | Reuters
Pfizer on Monday stated it filed a second lawsuit towards Novo Nordisk and Metsera, alleging that the Danish drugmaker’s try and outbid Pfizer to accumulate the weight problems biotech is anticompetitive.
Pfizer alleges that Ozempic maker Novo Nordisk’s proposed acquisition of Metsera would assist it preserve its dominant place within the blockbuster weight problems market by eliminating a smaller potential competitor, in response to the lawsuit filed Monday within the U.S. District Court docket in Delaware. The swimsuit additionally alleges that Metsera’s controlling shareholders conspired with the weight problems biotech and Novo Nordisk.
Novo Nordisk didn’t instantly reply to a request for remark.
In a assertion, Metsera stated, “Pfizer is attempting to litigate its approach to shopping for Metsera for a cheaper price than Novo Nordisk.” The corporate added that Pfizer’s litigation arguments “are nonsense, and Metsera will handle them in courtroom.”
The brand new swimsuit escalates a heated standoff between Pfizer and Novo Nordisk over Metsera, whose weight problems pipeline may yield new opponents within the booming weight reduction drug market. Pfizer in September stated that it might purchase Metsera for $4.9 billion, or as much as $7.3 billion with future funds – a deal that could possibly be the corporate’s golden ticket to enter the house after struggling to carry its personal weight problems merchandise to market.
However Novo Nordisk on Thursday launched a takeover bid valuing the biotech at round $6 billion, triggering a deadline of 4 enterprise days for Pfizer to renegotiate its provide. On Friday, Pfizer filed its first lawsuit towards Novo Nordisk and Metsera in search of to dam the biotech from terminating its current merger take care of Pfizer.
That swimsuit, filed within the Delaware Court docket of Chancery, alleges that Novo Nordisk’s provide cannot qualify as a superior proposal as a result of it is not moderately more likely to be accomplished because of its vital regulatory danger.
Novo Nordisk helped set up the load loss drug house, bringing to market extremely efficient GLP-1 medication, together with the diabetes injection Ozempic and weight problems shot Wegovy. However the firm has misplaced its main place out there to its chief rival, Eli Lilly, over the past 12 months and has struggled to impress traders with its pipeline.
Keep forward of the curve with NextBusiness 24. Discover extra tales, subscribe to our publication, and be part of our rising group at nextbusiness24.com